← All themes

Immunotherapy & Oncology

Cancer treatment has moved from poisoning dividing cells towards directing the immune system at the tumour, and towards drugs that carry their payload only to cancerous tissue. It absorbs more drug development spending than any other area.

388 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Johnson & Johnson JNJ $623B	3,792	+167	+5%	$320B
2	2 Pfizer PFE $169B	3,268	+180	+6%	$198B
3	3 Merck MRK $372B	3,238	+246	+8%	$211B
4	4 AbbVie ABBV $510B	3,171	+200	+7%	$198B
5	5 Bristol-Myers Squibb BMY $125B	2,602	+130	+5%	$114B
6	6 Amgen AMGN $238B	2,501	+177	+8%	$106B
7	7 Gilead Sciences GILD $197B	1,768	+164	+10%	$87.7B
8	8 Novartis NVS $287B	1,182	+94	+9%	$14.9B
9	9 Regeneron Pharmaceuticals REGN $83B	1,158	+78	+7%	$66.5B
10	10 AstraZeneca AZN $261B	1,062	+96	+10%	$34.1B
11	11 GSK GSK $99.3B	813	+71	+10%	$9.71B
12	12 Incyte INCY $23.1B	558	+21	+4%	$16.9B
13	13 DELISTED Exact Sciences EXAS	550	+70	+15%	$8.08B
14	SGEN 14 DELISTED Seagen Inc. Common Stock SGEN	537	-2	-0.4%	$21.4B
15	15 Jazz Pharmaceuticals JAZZ $14.1B	485	+17	+4%	$8.82B
16	16 Halozyme HALO $13.8B	422	+66	+19%	$7.27B
17	17 Exelixis EXEL $15.3B	387	-13	-3%	$4.42B
18	18 Lantheus LNTH $6.53B	364	+12	+3%	$3.29B
19	19 BioNTech BNTX $22.7B	319	+55	+21%	$6.02B
20	20 Qiagen QGEN $9.55B	296	0	0%	$6.73B
21	21 Guardant Health GH $22.2B	290	-38	-12%	$2.53B
22	22 Takeda Pharmaceutical TAK $63.3B	281	+5	+2%	$1.06B
23	23 Natera NTRA $57.8B	276	-11	-4%	$4.33B
24	24 NeoGenomics NEO $2.2B	242	-3	-1%	$1.02B
25	25 Genmab GMAB $23.4B	237	+43	+22%	$1.94B